Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IA-SUCCESS
2023-506935-14-01Phase 3Authorised
- Sponsor
- CHRU Nancy
- Start
- Sep 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of tissue-plasminogen activator in ischemic stroke (2 arms), sponsored by CHRU Nancy. Primary endpoint: Shift in modified Rankin Scale (mRS) at 90 days. Planned start Sep 2024; status: authorised.
02
Drugs
tissue-plasminogen activator
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on 2023-506935-14-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506935-14-01.